Longfeng Zhang

Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

Hongfu Cai, Longfeng Zhang, Na Li et al. · Clinical Therapeutics · 2019 · 50 citations

Medicine, Pathology, Bronchial Neoplasm +6

Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis

Hongfu Cai, Longfeng Zhang, Na Li et al. · Journal of Comparative Effectiveness Research · 2020 · 37 citations

Vimentin inhibits type I interferon production by disrupting the TBK1-IKKε-IRF3 axis

Hongyang Liu, Guangqiang Ye, Xiaohong Liu et al. · Cell Reports · 2022 · 37 citations · Full text

Wogonin inhibits in vitro herpes simplex virus type 1 and 2 infection by modulating cellular NF-κB and MAPK pathways

Ying Chu, Xiaowen Lv, Longfeng Zhang et al. · BMC Microbiology · 2020 · 36 citations · Full text

First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

Longfeng Zhang, Yongfu Hang, Maobai Liu et al. · Frontiers in Oncology · 2020 · 36 citations · Full text